The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.
Authors:
- Andrée-Laure HerrAHAndrée-Laure Herr
- Joyce RauchJRJoyce Rauch
- Carolyn NevilleCNCarolyn Neville
- Erika ChangECErika Chang
- Reda IbrahimRIReda Ibrahim
- Chantal SéguinCSChantal Séguin
- Jeannine KassisJKJeannine Kassis
- Lambert BusqueLBLambert Busque
- Paul R FortinPFPaul R Fortin
- 1 November 2003
- journal article
- Vol. 30 (11) , 2385-91
Abstract
To explore the effect of multiple prothrombotic risk factors in individuals with anticardiolipin antibodies (aCL), we evaluated immunologic, coagulation, and genetic prothrombotic abnormalities in a cohort of individuals with different aCL titers. We recruited 87 individuals into 4 categories (normal, low, intermediate, or high) based on their baseline IgG aCL (aCL-IgG) titers. We measured at followup: repeat aCL-IgG, IgM aCL (aCL-IgM), antibodies to beta2-glycoprotein I (anti-beta2-GPI), lupus anticoagulant (LAC) antibodies, protein C, protein S, activated protein C resistance, factor V506 Leiden mutation, methyl tetrahydrofolate reductase (MTHFR) C677T genotype, and prothrombin 20210A gene mutation. Thrombotic events were confirmed. At recruitment, 20 individuals were negative for aCL-IgG and 67 were positive (22 low, 20 intermediate, and 25 high titer). Twenty of the 87 participants had experienced a previous thrombotic event: 4 in the aCL-IgG negative group and 16 in the aCL-IgG positive group. Among the 87 individuals, the number of those with concomitant prothrombotic risk factors was as follows: 5 had no other prothrombotic risk factors, 32 had 1 risk factor, 24 had 2 risk factors, 10 had 3 risk factors, 10 had 4 risk factors, and 6 had 5 risk factors. Thrombotic events were observed in 20%, 13%, 33%, 10%, 30%, and 50% of these groups, respectively, and the odds ratio associated with a previous thrombotic event was 1.46 per each additional prothrombotic risk factor (95% confidence interval: 1.003-2.134). In individuals with positive aCL-IgG, we observed an association between the number of prothrombotic risk factors and history of thrombotic events.Keywords
This publication has 47 references indexed in Scilit:
- Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β 2-glycoprotein I-dependent mannerThe Journal of Immunology, 1996
- Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndromeBlood Coagulation & Fibrinolysis, 1996
- The Factor V Leiden Mutation which Predisposes to Thrombosis Is Not Common in Patients with Antiphospholipid SyndromeThrombosis and Haemostasis, 1995
- Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus ErythematosusThe American Journal of Medicine, 1995
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosusThe American Journal of Medicine, 1995
- Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor VThe Lancet, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous ThrombosisAnnals of Internal Medicine, 1992